kiniksa pharmaceuticals international plc - KNSA
KNSA
Close Chg Chg %
42.49 -0.49 -1.15%
Closed Market
42.00
-0.49 (1.15%)
Volume: 199.92K
Last Updated:
Dec 26, 2025, 4:00 PM EDT
Company Overview: kiniksa pharmaceuticals international plc - KNSA
KNSA Key Data
| Open $42.48 | Day Range 41.65 - 42.58 |
| 52 Week Range 17.82 - 44.42 | Market Cap $3.22B |
| Shares Outstanding 75.80M | Public Float 43.33M |
| Beta 0.01 | Rev. Per Employee N/A |
| P/E Ratio 94.76 | EPS $0.48 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 395.14K |
KNSA Performance
| 1 Week | -2.76% | ||
| 1 Month | -1.22% | ||
| 3 Months | 15.10% | ||
| 1 Year | 109.90% | ||
| 5 Years | 121.05% |
KNSA Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
7
Full Ratings ➔
About kiniksa pharmaceuticals international plc - KNSA
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
KNSA At a Glance
Kiniksa Pharmaceuticals International Plc
23 Old Bond Street
London, Greater London W1S 4PZ
| Phone | 44-781-431-9100 | Revenue | 423.24M | |
| Industry | Pharmaceuticals: Major | Net Income | -43,193,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 56.605% | |
| Fiscal Year-end | 12 / 2025 | Employees | 315 | |
| View SEC Filings |
KNSA Valuation
| P/E Current | 94.759 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.338 |
| Price to Book Ratio | 3.272 |
| Price to Cash Flow Ratio | 55.00 |
| Enterprise Value to EBITDA | -26.844 |
| Enterprise Value to Sales | 2.786 |
| Total Debt to Enterprise Value | 0.008 |
KNSA Efficiency
| Revenue/Employee | 1,343,615.873 |
| Income Per Employee | -137,120.635 |
| Receivables Turnover | 10.144 |
| Total Asset Turnover | 0.765 |
KNSA Liquidity
| Current Ratio | 3.298 |
| Quick Ratio | 3.035 |
| Cash Ratio | 2.421 |
KNSA Profitability
| Gross Margin | 55.186 |
| Operating Margin | -10.778 |
| Pretax Margin | -8.542 |
| Net Margin | -10.205 |
| Return on Assets | -7.804 |
| Return on Equity | -9.847 |
| Return on Total Capital | -9.635 |
| Return on Invested Capital | -9.651 |
KNSA Capital Structure
| Total Debt to Total Equity | 2.248 |
| Total Debt to Total Capital | 2.198 |
| Total Debt to Total Assets | 1.698 |
| Long-Term Debt to Equity | 1.793 |
| Long-Term Debt to Total Capital | 1.754 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Kiniksa Pharmaceuticals International Plc - KNSA
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 38.54M | 220.18M | 270.26M | 423.24M | |
Sales Growth
| - | +471.24% | +22.74% | +56.60% | |
Cost of Goods Sold (COGS) incl D&A
| 14.02M | 51.19M | 91.04M | 189.67M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 4.09M | 4.22M | 2.11M | 1.70M | |
Depreciation
| 4.09M | 4.22M | 1.11M | 448.00K | |
Amortization of Intangibles
| - | - | 1.00M | 1.25M | - |
COGS Growth
| +268.49% | +265.07% | +77.86% | +108.34% | |
Gross Income
| 24.52M | 168.99M | 179.22M | 233.57M | |
Gross Income Growth
| +744.49% | +589.12% | +6.05% | +30.33% | |
Gross Profit Margin
| +63.62% | +76.75% | +66.31% | +55.19% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 181.16M | 159.22M | 204.41M | 279.19M | |
Research & Development
| 97.84M | 64.31M | 74.99M | 111.17M | |
Other SG&A
| 83.32M | 94.91M | 129.43M | 168.01M | |
SGA Growth
| +17.97% | -12.11% | +28.38% | +36.58% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (156.64M) | 9.77M | (25.20M) | (45.62M) | |
Non Operating Income/Expense
| 97.00K | 1.25M | 8.54M | 9.46M | |
Non-Operating Interest Income
| - | 97.00K | 8.54M | 9.46M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (156.54M) | 11.03M | (16.65M) | (36.15M) | |
Pretax Income Growth
| -0.20% | +107.04% | -251.02% | -117.10% | |
Pretax Margin
| -406.13% | +5.01% | -6.16% | -8.54% | |
Income Tax
| 1.39M | (172.34M) | (30.74M) | 7.04M | |
Income Tax - Current - Domestic
| 1.39M | 8.83M | 1.25M | (1.21M) | |
Income Tax - Current - Foreign
| (14.00K) | 4.33M | 1.80M | 117.00K | |
Income Tax - Deferred - Domestic
| - | - | (18.08M) | (1.74M) | - |
Income Tax - Deferred - Foreign
| 11.00K | (185.50M) | (15.71M) | 9.87M | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (157.92M) | 183.36M | 14.08M | (43.19M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (157.92M) | 183.36M | 14.08M | (43.19M) | |
Net Income Growth
| +2.14% | +216.11% | -92.32% | -406.68% | |
Net Margin Growth
| -409.72% | +83.28% | +5.21% | -10.21% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (157.92M) | 183.36M | 14.08M | (43.19M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (157.92M) | 183.36M | 14.08M | (43.19M) | |
EPS (Basic)
| -2.3029 | 2.6428 | 0.201 | -0.6047 | |
EPS (Basic) Growth
| +11.75% | +214.76% | -92.39% | -400.85% | |
Basic Shares Outstanding
| 68.58M | 69.38M | 70.06M | 71.42M | |
EPS (Diluted)
| -2.3029 | 2.6038 | 0.1958 | -0.6047 | |
EPS (Diluted) Growth
| +11.75% | +213.07% | -92.48% | -408.84% | |
Diluted Shares Outstanding
| 68.58M | 70.42M | 71.92M | 71.42M | |
EBITDA
| (152.55M) | 13.99M | (23.09M) | (43.92M) | |
EBITDA Growth
| +0.66% | +109.17% | -264.99% | -90.24% | |
EBITDA Margin
| -395.78% | +6.36% | -8.54% | -10.38% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 54.00 | |
| Number of Ratings | 7 | Current Quarters Estimate | 0.366 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | 1.005 | |
| Last Quarter’s Earnings | 0.23 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.60 | Next Fiscal Year Estimate | 1.635 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 7 | 5 | 7 | 7 |
| Mean Estimate | 0.37 | 0.32 | 1.01 | 1.63 |
| High Estimates | 0.55 | 0.45 | 1.47 | 2.43 |
| Low Estimate | 0.27 | 0.26 | 0.86 | 1.22 |
| Coefficient of Variance | 28.36 | 24.51 | 21.19 | 25.96 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 7 | 7 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Kiniksa Pharmaceuticals International Plc - KNSA
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Kiniksa Pharmaceuticals International Plc - KNSA
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 4, 2025 | Sanj K. Patel CHAIRMAN & CEO; Director | 94,531 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $21.77 per share | 2,057,939.87 |
| Apr 4, 2025 | Ross Moat CHIEF COMMERCIAL OFFICER | 5,221 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | John F. Paolini CHIEF MEDICAL OFFICER | 56,153 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $21.77 per share | 1,222,450.81 |
| Apr 4, 2025 | John F. Paolini CHIEF MEDICAL OFFICER | 56,630 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | John F. Paolini CHIEF MEDICAL OFFICER | 54,880 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Sanj K. Patel CHAIRMAN & CEO; Director | 18,712 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Sanj K. Patel CHAIRMAN & CEO; Director | 12,962 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Sanj K. Patel CHAIRMAN & CEO; Director | 68,869 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Sanj K. Patel CHAIRMAN & CEO; Director | 34,435 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Sanj K. Patel CHAIRMAN & CEO; Director | 137,638 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Sanj K. Patel CHAIRMAN & CEO; Director | 91,514 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $21.77 per share | 1,992,259.78 |
| Apr 4, 2025 | Michael R. Megna CHIEF ACCOUNTING OFFICER | 30,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Sanj K. Patel CHAIRMAN & CEO; Director | 96,835 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Sanj K. Patel CHAIRMAN & CEO; Director | 90,597 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Michael R. Megna CHIEF ACCOUNTING OFFICER | 7,087 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Michael R. Megna CHIEF ACCOUNTING OFFICER | 5,115 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Michael R. Megna CHIEF ACCOUNTING OFFICER | 10,575 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Michael R. Megna CHIEF ACCOUNTING OFFICER | 21,150 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Michael R. Megna CHIEF ACCOUNTING OFFICER | 30,279 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $21.77 per share | 659,173.83 |
| Apr 4, 2025 | Michael R. Megna CHIEF ACCOUNTING OFFICER | 31,280 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $21.77 per share | 680,965.60 |